Abstract
Background: High sodium intake has been considered as the leading dietary risk factor for deaths and disability-adjusted life-years among older adults. High-quality randomized trials to evaluate the effects of practical sodium reduction strategies are needed. Methods: The study is a cluster randomized trial with a 2 × 2 factorial design conducted in 48 senior residential facilities in northern China. These facilities are randomly assigned (1:1:1:1) to 1 of 4 groups: stepwise salt supply control (SSSC) in which 5%-10% of the study salt supply in the institutional kitchens will be reduced every 3 months, replacing normal salt with salt substitute (SS); SSSC only; SS only; or neither SSSC nor SS. The interventions last for 2 years with follow-up every 6 months. The primary outcome is the change in systolic blood pressure from baseline to 24 months. Secondary outcomes include the incidence of hyperkalemia, hyponatremia, cardiovascular events, and death. Current status: The study has recruited and randomized 48 senior residential facilities with 1,606 participants. Mean age at baseline was 71 years, and 76% are male. Both types of salt intervention were initiated in the study facilities between January and April 2018. Conclusion: The study is well placed to define the effects of 2 practical and scalable sodium reduction strategies for blood pressure reduction and will provide important new data about safety of these strategies among older adults in China.
Original language | English (US) |
---|---|
Pages (from-to) | 198-205 |
Number of pages | 8 |
Journal | American heart journal |
Volume | 226 |
DOIs | |
State | Published - Aug 2020 |
Funding
This work was supported by the National Key Research and Development Program, Ministry of Science and Technology of China , through the research grant “Diet, ExerCIse and CarDiovascular hEalth, DECIDE project” ( 2016YFC1300200 ). Aoming Jin was supported by China Scholarship Council ( 201806010389 ). The funding agencies have no role in writing and publishing this article. The authors are solely responsible for the design, data collection, data analyses, and publication of this study. Yangfeng Wu received a small research grant to evaluate the efficacy and safety of a novel salt substitute manufactured by the Health Source (Chongqing) Cardiovascular Health Technology Co. The other authors declare that there is no conflict of interest.
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine